THERAPY DOSSIER · th-4e254066697e

Danhong injection, a standardised Chinese Materia Medica product extracted from Radix Salviae miltiorrhizae and Flos Carthami tinctorii

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01677208 ↗PHASE4completed

Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in Acute Ischemic Stroke

Acute Stroke

Enrolment: 1503 · Results not recorded

NCT01681316 ↗PHASE4completed

Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in Chronic Stable Angina

Chronic Stable Angina

Enrolment: 920 · Results not recorded

NCT02152280 ↗PHASE4unknown

A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke

Stroke

Enrolment: 320 · Results not recorded

NCT02158559 ↗PHASE4unknown

Effect of Danhong Injection on Microcirculation in STEMI Patients After PTCA

Myocardial Infarction

Enrolment: 180 · Results not recorded

NCT02007187 ↗PHASE4completed

Randomized, Double-blind, Multicenter, Parallel Controlled Trial of Danhong Injection in Unstable Angina Pectoris

Unstable Angina Pectoris

Enrolment: 160 · Results not recorded

NCT02176395 ↗PHASE4completed

Multi-Omics Research of Danhong Injection to Treat Acute Ischemic Stroke

Acute Stroke

Enrolment: 46 · Results not recorded

NCT07375862 ↗PHASE2not yet recruiting

Clinical Benefits and Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction

Sepsis-Induced Myocardial Dysfunction

Enrolment: 140 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25069640 ↗2014Reported benefit

Danhong injection attenuates ischemia/reperfusion-induced brain damage which is associating with Nrf2 levels in vivo and in vitro.

RatIschaemia-reperfusionCerebral (MCAO/stroke)WistarMale0.9 ml/kg (DHI-L) and 1.8 ml/kg (DHI-H)

Model: Cerebral ischaemia/reperfusion injury induced by middle cerebral artery occlusion; in vitro model of H2O2-wounded mouse Neuro-2A cells

Danhong injection ameliorated neurological score, cerebral infarction and brain oedema, increased SOD and GSH, decreased MDA, and upregulated Nrf2, HO-1 and NQO1 expression in ischaemic brain tissue in vivo. In vitro it increased Nrf2 and HO-1 mRNA transcription and upregulated Nrf2 protein. The au…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…